BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19615897)

  • 21. Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.
    Lawson M; Rodrigo J; Baratte B; Robert T; Delehouzé C; Lozach O; Ruchaud S; Bach S; Brion JD; Alami M; Hamze A
    Eur J Med Chem; 2016 Nov; 123():105-114. PubMed ID: 27474927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents.
    Kassis P; Brzeszcz J; Bénéteau V; Lozach O; Meijer L; Le Guével R; Guillouzo C; Lewiński K; Bourg S; Colliandre L; Routier S; Mérour JY
    Eur J Med Chem; 2011 Nov; 46(11):5416-34. PubMed ID: 21944287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and Aurora-A kinase inhibitors for anti-cancer agents.
    Fu RG; You QD; Yang L; Wu WT; Jiang C; Xu XL
    Bioorg Med Chem; 2010 Nov; 18(22):8035-43. PubMed ID: 20934346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.
    Koo KA; Kim ND; Chon YS; Jung MS; Lee BJ; Kim JH; Song WJ
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2324-8. PubMed ID: 19282176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
    Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
    Kendall JD; Giddens AC; Tsang KY; Frédérick R; Marshall ES; Singh R; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
    Bioorg Med Chem; 2012 Jan; 20(1):58-68. PubMed ID: 22177407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).
    Witherington J; Bordas V; Garland SL; Hickey DM; Ife RJ; Liddle J; Saunders M; Smith DG; Ward RW
    Bioorg Med Chem Lett; 2003 May; 13(9):1577-80. PubMed ID: 12699759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
    Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
    Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.
    Pfaffenrot B; Klövekorn P; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
    Eur J Med Chem; 2021 Jun; 218():113371. PubMed ID: 33794385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases.
    Misra RN; Rawlins DB; Xiao HY; Shan W; Bursuker I; Kellar KA; Mulheron JG; Sack JS; Tokarski JS; Kimball SD; Webster KR
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1133-6. PubMed ID: 12643928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
    Kim DK; Lee YI; Lee YW; Dewang PM; Sheen YY; Kim YW; Park HJ; Yoo J; Lee HS; Kim YK
    Bioorg Med Chem; 2010 Jun; 18(12):4459-67. PubMed ID: 20472445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.
    Qiao L; Choi S; Case A; Gainer TG; Seyb K; Glicksman MA; Lo DC; Stein RL; Cuny GD
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6122-6. PubMed ID: 19783434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.
    Park BS; El-Deeb IM; Yoo KH; Oh CH; Cho SJ; Han DK; Lee HS; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4720-3. PubMed ID: 19596575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Casein kinase 1/Checkpoint kinase 1 pyrazolo-pyridine protein kinase inhibitor as novel activator of the p53 pathway.
    Huart AS; Saxty B; Merritt A; Nekulova M; Lewis S; Huang Y; Vojtesek B; Kettleborough C; Hupp TR
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5578-85. PubMed ID: 24007918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suzuki-type Pd(0) coupling reactions in the synthesis of 2-arylpurines as Cdk inhibitors.
    Vandromme L; Piguel S; Lozach O; Meijer L; Legraverend M; Grierson DS
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3144-6. PubMed ID: 16616489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regioselective acylation of congeners of 3-amino-1H-pyrazolo[3,4-b]quinolines, their activity on bacterial serine/threonine protein kinases and in vitro antibacterial (including antimycobacterial) activity.
    Lapa GB; Bekker OB; Mirchink EP; Danilenko VN; Preobrazhenskaya MN
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1088-93. PubMed ID: 22957725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of N,N'-bis(5-arylidene-4-oxo-3,5-dihydro-4H-imidazol-2-yl)diamines bearing various linkers and biological evaluation as potential inhibitors of kinases.
    Coulibaly WK; Paquin L; Bénie A; Bekro YA; Durieu E; Meijer L; Bazureau JP
    Eur J Med Chem; 2012 Dec; 58():581-90. PubMed ID: 23174317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Mohan AV; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6049-53. PubMed ID: 21911290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).
    Deng X; S Gray N
    Expert Opin Ther Pat; 2012 Jun; 22(6):709-13. PubMed ID: 22607035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
    Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.